Chongqing Genrix Biopharma Co., Ltd. (688443)

Overview

Chongqing Genrix Biopharmaceutical Co., Ltd. is a pioneering biopharmaceutical entity based in Chongqing, China. Since its inception in 2015, the company has devoted itself to the task of advancing the development, production, and commercialization of antibody drugs. These efforts are aimed not only to meet the growing demands within China’s pharmaceutical landscape but also to address critical healthcare needs involving various diseases. Through its dedicated research and development activities, Genrix has established a strong pipeline of novel antibody therapies designed to combat a range of conditions, thereby underscoring its essential role in the realm of biopharmaceuticals.

Products and Services

• GR1501: A monoclonal antibody specifically designed for the treatment of axial spondylarthritis, potentially offering new hope for patients suffering from this chronic inflammatory disease.
• GR1801: This innovative anti-rabies virus G protein bispecific antibody aims to provide a more effective prophylactic or therapeutic solution against the deadly rabies virus.
• GR1802: An anti-IL-4Ra monoclonal antibody developed to target key pathways involved in various allergic and inflammatory diseases, illustrating the company's commitment to addressing complex immunological disorders.
• GR1603: A monoclonal antibody intended for patients with systemic lupus erythematosus, offering a novel approach to managing this autoimmune condition.
• GR2002: This anti-TSLP bispecific antibody represents a significant advancement in treating diseases characterized by TSLP-mediated pathologies, focusing on a novel therapeutic target.
• WM1R3: A family receptor bispecific antibody, together showing the breadth of Genrix's exploration into bispecific antibody technologies for enhancing drug efficacy and specificity.
• GR2001: A monoclonal antibody, highlighting the company’s ongoing pursuit of new molecular targets for therapeutic intervention.
• GR2201: Specifically developed as a monoclonal antibody for VZV (Varicella Zoster Virus) infection, offering advancements in treating and preventing shingles or chickenpox.
• GR1803: A bispecific antibody for multiple myeloma, aiming to introduce a novel treatment option for this type of blood cancer, showing promise for improved patient outcomes.
• GR1901: Another significant addition to the bispecific antibody portfolio, though its specific target and application are not described, it underscores Genrix’s versatility in antibody development.
• WM202 and WM215: Represent advancements in bispecific and single-domain antibody technologies, respectively, catering to a range of therapeutic applications with enhanced targeting capabilities.
• GR1401: An anti-EGFR monoclonal antibody, developed for the treatment of cancers with over-expression or aberrant activation of the EGFR pathway, showing the company's involvement in oncology.
• GR1405: An anti-PD-L1 monoclonal antibody, contributing to the expanding field of immuno-oncology by targeting the PD-L1 pathway to enhance the anti-tumor immune response in cancer patients.